[Correspondence] The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer – Authors' reply

We thank John P Neoptolemos and colleagues for their letter. They state that the ESPAC-1 trial set the standard of care for adjuvant therapy in resectable pancreatic cancer.1 However, ESPAC-1 set the standard of care for resected pancreatic cancer, including only those patients who had no occult metastases at surgery, underwent a resection, recovered from surgery, had no early recurrence, and remained fit for adjuvant treatment. In the adjuvant group of nine randomised controlled trials comparing neoadjuvant with adjuvant therapy, only 80% of all patients with resectable pancreatic cancer became patients with resected pancreatic cancer.